NTN Buzztime Inc (BTX)

COMMUNICATIONS: ENTERTAINMENT
SIC: PHARMACEUTICAL PREPARATIONS

140 58TH STREET, BUILDING A BROOKLYN, NY 11220

Brooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. The company is also exploring opportunities to advance therapies using leading edge gene editing/cell therapy technology through its option agreements with Factor Bioscience and Novellus. Brooklyn’s most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.

Data as of 2021-10-17 09:04:41 -0400
Market Cap473.326 Million Shares Outstanding51.73 Million Avg 30-day Volume702.281 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE Enterprise Value
Total Cash Current Debt Gross Profit
BETA0.0 52-week High/Low80.67 / 3.5 Next Earnings Date2021-11-11 Price to Cash FLow (P/CF) -9999999.0
Data provided by IEX Cloud
View SEC Filings from BTX instead.

View recent insider trading info

Funds Holding BTX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding BTX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SIDHU ROGER SEE REMARKS

0 2021-09-20 2

SIAL JAY SEE REMARKS

0 2021-07-15 2

DENNY GEORGE P III

  • 10% Owner
4,097 2021-07-06 2

DAMOUR KEVIN SEE REMARKS

0 2021-06-28 2

GURROLA SANDRA M VICE PRESIDENT OF FINANCE

8,203 2021-06-21 9

CHERINGTON CHARLES

5,894,101 2021-06-16 2

MOHR ERICH

0 2021-05-06 1

LANGER DENNIS

0 2021-05-01 1

FEDEROFF HOWARD J. SEE REMARKS

0 2021-04-16 2

HALPERN JOHN D

HALPERN KATHERINE H.

  • 10% Owner
4,780,307 2021-03-25 1

MONOVOUKAS YIANNIS

560,453 2021-03-25 1

SINGER NICHOLAS JASON

3,791,983 2021-03-25 1

MASON LYNN SADOWSKI SEE REMARKS

94,333 2021-03-25 1

GUIDO RONALD SEE REMARKS

102,112 2021-03-25 1

GREENWOOD LUBA

50,032 2021-03-25 1

WOLFF ALLEN FORMER DIRECTOR AND CEO

132,720 2021-03-24 7

ELLIN ROBERT S

  • 10% Owner
16,615 2020-08-13 0

BERG JEFFREY ALAN

  • 10% Owner
288,446 2020-06-03 0

SIMTOB RICHARD ISAAC

  • Director
56,094 2019-12-31 0

GOTTLIEB MICHAEL

  • Director
18,986 2019-11-26 0

MILLER SUSAN ELAINE

  • Director
0 2019-08-30 0

KRISHNAN RAM CEO

  • Officer
  • Director
102,375 2019-08-27 0

MITGANG STEVE

  • Director
0 2019-06-07 0

YANOVER PAUL

  • Director
0 2019-06-07 0

THOMAS GREGORY MATTHEW

  • Director
0 2019-06-07 0

AWM INVESTMENT COMPANY, INC.

  • 10% Owner
No longer subject to file 2018-03-12 0

LEWIS MARY BETH

  • Director
0 2017-06-08 0

UPHOFF TONY

  • Director
0 2017-06-08 0

MILLER DAVE BRIAN SVP MARKETING

  • Officer
13,131 2016-11-04 0

THOMAS WILLIAM SVP MARKETING

  • Officer
0 2014-05-12 0

KHUCHUA VLADIMIR CHIEF DEVELOPMENT OFFICER

  • Officer
0 2014-05-05 0

COONEY ROBERT J CHIEF OPERATING OFFICER

  • Officer
0 2014-01-23 0

NAGAMINE KIRK CHIEF REVENUE OFFICER

  • Officer
0 2013-04-15 0

CHANDLER BARRY CHIEF MARKETING OFFICER

  • Officer
250,000 2013-01-31 0

BERGER KENDRA CHIEF FINANCIAL OFFICER

  • Officer
188,750 2012-08-06 0

GEORGE CHRISTOPHER ALLEN CHIEF INFORMATION OFFICER

  • Officer
60,600 2012-08-06 0

BATEMAN TERRY ALLAN

  • Director
0 2012-06-08 0

DUCKETT PETER A. SVP OF SALES

  • Officer
0 2012-03-26 0

BUSH MICHAEL J CEO

  • Officer
  • Director
420,385 2012-02-24 0

GLASSMAN NICHOLAS A EVP OF PROGRAMMING/TECHNOLOGY

  • Officer
0 2010-05-10 0

FIDELITY NATIONAL FINANCIAL, INC.

  • 10% Owner
No longer subject to file 2009-08-19 0

KEYMER KENNETH L CHIEF OPERATIONS OFFICER

  • Officer
0 2009-07-27 0

FARRICIELLI JOSEPH J. JR.

  • Director
110,000 2009-06-15 0

TRINAD CAPITAL MASTER FUND LTD.

TRINAD ADVISORS II, LLC

TRINAD CAPITAL L.P.

TRINAD MANAGEMENT, LLC

ELLIN ROBERT S

WOLF JAY

  • 10% Owner
8,900,093 2009-05-15 0

RAMACHANDRAN KARTIK V. CHIEF STRAT OFF, EVP BUS DEV

  • Officer
0 2009-04-24 0

ARZT MICHAEL A EXECUTIVE VP OF MARKETING

  • Officer
0 2009-01-30 0

ARLEN GARY H

  • Director
10,450 2008-12-19 0

CLASEN ROBERT B

  • Director
60,000 2008-09-09 0

BERGSMAN BARRY

  • Director
142,000 2008-09-05 0

TAUBER JAKE EVP CONTENT & MARKETING

  • Officer
18,750 2008-08-12 0

BOYLAN PETER JAMES III EXECUTIVE VICE PRESIDENT SALES

  • Officer
0 2008-07-15 0

FLEMING MICHAEL K INTERIM CEO

  • Officer
  • Director
0 2008-06-09 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

SIDHU ROGER SEE REMARKS

2021-09-22 16:57:24 -0400 2021-09-20 A 161,300 a 161,300 direct

SIDHU ROGER SEE REMARKS

2021-09-22 16:57:24 -0400 2021-09-20 A 80,650 a 80,650 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
BROOKLYN IMMUNOTHERAPEUTICS BTX 2021-10-20 13:45:03 UTC -14.9881 15.0581 350000
BROOKLYN IMMUNOTHERAPEUTICS BTX 2021-10-20 13:15:03 UTC -14.9881 15.0581 350000
BROOKLYN IMMUNOTHERAPEUTICS BTX 2021-10-20 12:45:03 UTC -14.9881 15.0581 350000
BROOKLYN IMMUNOTHERAPEUTICS BTX 2021-10-19 22:15:03 UTC -14.9881 15.0581 500000
BROOKLYN IMMUNOTHERAPEUTICS BTX 2021-10-19 21:45:03 UTC -14.9881 15.0581 500000
BROOKLYN IMMUNOTHERAPEUTICS BTX 2021-10-19 21:15:03 UTC -14.9881 15.0581 500000
BROOKLYN IMMUNOTHERAPEUTICS BTX 2021-10-19 20:45:03 UTC -14.9881 15.0581 500000
BROOKLYN IMMUNOTHERAPEUTICS BTX 2021-10-19 20:15:03 UTC -14.9881 15.0581 500000
BROOKLYN IMMUNOTHERAPEUTICS BTX 2021-10-19 19:45:03 UTC -14.9881 15.0581 500000
BROOKLYN IMMUNOTHERAPEUTICS BTX 2021-10-19 19:15:03 UTC -14.9881 15.0581 500000
BROOKLYN IMMUNOTHERAPEUTICS BTX 2021-10-19 18:45:03 UTC -14.9881 15.0581 500000
BROOKLYN IMMUNOTHERAPEUTICS BTX 2021-10-19 18:15:03 UTC -14.9881 15.0581 500000
BROOKLYN IMMUNOTHERAPEUTICS BTX 2021-10-19 17:45:03 UTC -14.9881 15.0581 500000
BROOKLYN IMMUNOTHERAPEUTICS BTX 2021-10-19 17:15:03 UTC -14.9881 15.0581 500000
BROOKLYN IMMUNOTHERAPEUTICS BTX 2021-10-19 16:45:03 UTC -14.9881 15.0581 500000
BROOKLYN IMMUNOTHERAPEUTICS BTX 2021-10-19 16:15:03 UTC -14.9881 15.0581 500000
BROOKLYN IMMUNOTHERAPEUTICS BTX 2021-10-19 15:45:03 UTC -14.9881 15.0581 500000
BROOKLYN IMMUNOTHERAPEUTICS BTX 2021-10-19 15:15:03 UTC -14.9881 15.0581 450000
BROOKLYN IMMUNOTHERAPEUTICS BTX 2021-10-19 14:45:03 UTC -14.9881 15.0581 450000
BROOKLYN IMMUNOTHERAPEUTICS BTX 2021-10-19 14:15:04 UTC -14.9881 15.0581 450000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
Weiss Strategic Interval Fund- Weiss Strategic Interval Fund BTX -22.0 shares, $-396.22 2021-06-30 N-PORT
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund BTX -1950.0 shares, $-35119.5 2021-06-30 N-PORT

Elevate your investments